Anti-cancer troops! Targeted new drugs will be on the market within five years.

Cancer is the public enemy of the whole people, killing tens of thousands of people every year. MPT0E028, a new anticancer drug developed by Taipei Medical College, is the first university in Taiwan Province Province and has entered human clinical trials. It is expected to enter the second phase of clinical trials next year, and it will be listed in five years at the earliest, which is expected to add a powerful new force to the global cancer targeted therapy and open a chance for cancer patients.

The new targeted anticancer drug MPT0E028 and its preparation (pictured) have entered human clinical trials. (Photo courtesy of Taipei Medical College) MPT0E028, developed by Professor Liu Jingping, Vice President of College of Pharmacy, Taipei Medical College, is a small molecule new drug of pan-HDAC (histone deacetylase) inhibitor, which can inhibit the activity of histone deacetylase. It shows the activity of inhibiting the growth of cancer cells in animal models of colorectal cancer, liver cancer, lung cancer, lymphoma and pancreatic cancer, and has anti-tumor effect.

Animal experiments show that it can inhibit tumor activity.

Clinically, HDAC exists in normal cells of human body. Once suffering from cancer, the activity of HDAC is abnormally increased, which reduces the activity of tumor suppressor genes in vivo. Animal experiments show that MPT0E028 can inhibit the activity of HDAC and promote the apoptosis of cancer cells, thus achieving the positive purpose of relieving or treating cancer.

At present, it has obtained patents from Taiwan Province Province of China and the United States, and completed patent applications from European Union, Russian Federation, Australia and other 19 countries and regions. It is estimated that the license fee will exceed NT$ 480 million, which is highly recognized and favored by international and biotechnology operators.